Cancer Venous Thromboembolism (VTE)

Official Title

Cancer Venous Thromboembolism (VTE)


Edoxaban will be similar to dalteparin in preventing recurrence of acute VTE following an initial index event in cancer subjects.

Trial Description

Primary Outcome Measures:

  • incidence of recurrent VTE at end of study
  • incidence of of clinically relevant bleeding while on treatment 

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society